|
|
||||||||
National Laboratory of DNA Medicine, Division of Molecular and Life Science, Pohang University of Science and Technology, Hyoja Dong, Pohang, Korea
| Abstract |
|---|
|
|
|---|
secretion from activated T cells. It was also reported that
IL-12 prevents apoptosis of CD4+ T cells. However, the
signaling mechanism that regulates these IL-12-induced responses is
poorly understood yet. In this study, we demonstrated that IL-12
activates phosphatidylinositol 3-kinase (PI3K)/Akt pathway in murine
CD4+ T cells, and that this signaling pathway is required
for IL-12-induced T cell proliferation and antiapoptotic function, but
not for IFN-
induction. Through PI3K/Akt pathway, IL-12 up-regulates
the expression of cell cycle-related molecule such as cyclin D3, and
antiapoptotic molecules such as Bcl-2 and cellular inhibitors of
apoptosis proteins-2, followed by down-regulation of active
caspase-3. These results suggest that PI3K/Akt pathway is critical for
mediating IL-12-induced CD4+ T cell responses such as T
cell proliferation and survival. | Introduction |
|---|
|
|
|---|
secretion from activated T
and NK cells (1, 2, 3, 4, 5). In addition, it has been reported
that IL-12 prevents apoptotic cell death of the activated human and
mouse peripheral T cells (6, 7, 8, 9).
IL-12R is composed of two subunits, designated
1 and
2. IL-12
activates the Janus family of protein tyrosine kinases
(Jaks)3 such as Jak2
and Tyk2 through IL-12R (10). These activated Jaks
phosphorylate tyrosine residues on IL-12R
2, providing docking sites
for the Src homology 2 domain of STAT-4, and then STAT-4 is
phosphorylated and dimerized to bind to the IL-12-responsive genes
(11). STAT-4 appears to be an important mediator in IL-12R
signaling, because IL-12-induced IFN-
secretion and T cell
proliferation are impaired in STAT-4-/- mice
(5). Besides the Jak-STAT pathway, IL-12 was also shown to
activate mitogen-activated protein kinase (MAPK) kinase (MKK) 6/p38
MAPK pathway, but not extracellular signal-regulated kinases (Erk) 1/2
or c-Jun N-terminal kinase pathway (12, 13). In
particular, MKK 6/p38 MAPK pathway is required to promote IL-12-induced
IFN-
secretion and STAT-4 serine phosphorylation on serine 721, but
not T cell proliferation (12, 13, 14, 15). These results suggest
that IL-12 might activate multiple signaling pathways for a variety of
IL-12-induced T cell responses.
Many cytokines and growth factors activate phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in T cells (16). In mammalian cells, multiple isoforms of PI3K were found and subdivided into three classes. Among them, class I PI3Ks are generally coupled to extracellular stimuli and transmit signals to induce protein synthesis, cytoskeletal changes, cell cycle regulation, and apoptosis regulation (17). In the case of IL-2R signaling, it was reported that PI3K/Akt pathway activated by IL-2 regulates cell cycle-related molecules such as cyclin D3 and p27kip1 to induce T cell proliferation (18). Recently, it was also shown that PI3K/Akt pathway activated by IL-2 family cytokines such as IL-2, IL-4, and IL-15 promotes T cell survival through the modulation of an antiapoptotic molecule such as Bcl-2 (19). However, it is not clear yet whether IL-12 activates the PI3K/Akt pathway, leading to the modulation of IL-12-induced T cell responses. In this study, we clearly demonstrated that IL-12 stimulates the PI3K/Akt signaling pathway in activated CD4+ T cells, and that this signaling pathway is critical for IL-12-induced T cell proliferation and inhibition of apoptosis. In particular, IL-12 modulates the expression of cell cycle-related molecule such as cyclin D3, and antiapoptotic molecules such as Bcl-2 and cellular inhibitors of apoptosis proteins (cIAP)-2 through PI3K/Akt pathway.
| Materials and Methods |
|---|
|
|
|---|
Five- to 10-wk-old C57BL/6 female mice were purchased from Japan SLC (Shizuoka, Japan) and used for the isolation of lymph nodes (LNs). The mice were maintained in specific pathogen-free conditions and fed autoclaved food and water.
Reagents and Abs
For MACS, anti-mouse CD11b, MHC class II, CD8, and B220
microbeads were obtained from Miltenyi Biotec (Auburn, CA). Purified
hamster anti-mouse CD3e and CD28 NA/LE Abs were purchased from
Southern Biotechnology Associates (Birmingham, AL). For the flow
cytometric analysis and cytokine ELISA, anti-mouse CD4 FITC, active
caspase 3 FITC, annexin V FITC, and anti-mouse IFN-
capture and
detection Abs were purchased from BD PharMingen (San Diego, CA).
Recombinant mouse IL-2, IL-4, and IL-12 were all obtained from R&D
Systems (Minneapolis, MN) and reconstituted as described in
technological notes. General reagents used were purchased from
Sigma-Aldrich (St. Louis, MO), unless otherwise indicated. SB203580 and
LY294002 were purchased from Calbiochem (La Jolla, CA). RPMI 1640 and
FBS were purchased from Life Technologies (Grand Island, NY) and
HyClone Laboratories (Logan, UT), respectively. For immunoblot assay,
rabbit Abs against p38 MAPK, Erks, Akt,
Thr180/Tyr182-phosphorylated
p38 MAPK,
Thr202/Tyr204-phosphorylated
Erks, and
Ser473/Thr308-phosphorylated
Akt were all purchased from New England Biolabs (Beverly, MA). Rabbit
Abs against STAT-4 and cIAP-1/2 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse Abs against
p27kip1, Bcl-2, and cyclin D3 were also obtained
from Santa Cruz Biotechnology. For IFN-
response region (GRR)
affinity purification, streptavidin-agarose beads were obtained from
Sigma-Aldrich.
Preparation of murine primary CD4+ T lymphocytes
Mouse naive CD4+ T cells were purified from the LNs of C57BL/6 female mice. CD4+ T cells were negative selected through VS+ columns using the high gradient MACS (Miltenyi Biotec), as described previously (20). Briefly, harvested LN cells were treated with ammonium chloride lysing buffer to clear RBC. Then remaining cells were treated with anti-CD11b, anti-MHC class II, anti-B220, and anti-CD8 microbeads, and purified by negative selection using the MACS Separation System. Purified cell populations were 92% CD4+ T cells. The purity was assessed by flow cytometric analysis on a FACScan flow cytometer (BD Biosciences, Heidelberg, Germany) after staining with anti-CD4 FITC Abs.
In vitro activation and culture of CD4+ T cells
Purified CD4+ T cells were in vitro activated for 72 h with plate-bound anti-CD3 (300 ng/well) and anti-CD28 (100 ng/well) hamster Abs in 96-well plate. T cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS (HyClone Laboratories), 2 mM L-glutamine, 50 mM 2-ME, and antibiotics (50 U/ml penicillin and 50 µg/ml streptomycin). The Ab-activated CD4+ T cells were harvested and washed twice with complete medium and used for the following experiments.
Preparation of whole cell lysates and immunoblot analysis
The Ab-activated T cells (5 x 106
cells/ml) were pretreated for 20 min with medium alone, 5 µM
LY294002, or 10 µM SB203580 (Calbiochem). After pretreatment, T cells
were incubated with medium, 20 ng/ml IL-2, 100 ng/ml IL-4, or 10 ng/ml
IL-12p70 (R&D Systems) for the indicated times. Then cells were
harvested and whole cell lysates were prepared, as described previously
(10). To quantify the phosphorylation of Akt, p38 MAPK,
and Erks, equal amounts of whole cell lysates were resolved by 10%
SDS-PAGE. Then Western blots were immunoanalyzed using specific Abs
against the phosphorylated form of each protein. To confirm that the
same amount of proteins was loaded in each lane, primary Ab/secondary
Ab complex was removed, as described previously (21). The
blots were then subjected to autoradiography to confirm that the Ab
signal had been removed. After this procedure, the blots were reprobed
with the specific Abs against total Akt, p38 MAPK, or Erks. For cell
cycle and antiapoptotic molecules, we used each indicated Ab or
-actin as a control, followed by goat anti-rabbit or mouse
HRP-conjugated Abs.
Cytokine ELISA and intracellular staining
Murine IFN-
ELISA was performed as described in the
recommended protocol (BD PharMingen).
Ab-activated T cells were harvested and treated with indicated inhibitors and cytokines. At 36 h after treatment, cells were collected and washed twice with PBS. Cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD PharMingen) for 20 min at 4°C, and then washed with Perm/Wash buffer (BD PharMingen). Permeabilized cells were resuspended with the wash buffer containing FITC-conjugated rabbit anti-mouse active caspase-3 Abs (BD PharMingen), and incubated for 30 min at 4°C. After incubation, cells were harvested and resuspended with PBS containing 0.5% FBS and 0.1% sodium azide. Intracellular active caspase-3 levels were assessed by flow cytometry.
Oligonucleotide affinity purification and immunoblotting
Oligonucleotide affinity purification of STAT-4 proteins was
performed using a 5'-biotinylated double-stranded oligonucleotide
corresponding to the GRR of mouse Fc
RI gene (22, 23),
coupled to streptavidin-agarose. Briefly, 20 min after cytokine
stimulation, whole cell lysates were prepared by lysis of cells in a
lysis buffer comprised of 50 mM Tris-Cl (pH 8.0), 1% Nonidet P-40, 15
mM NaCl, 0.1 mM EDTA, 10 mM NaF, 10% glycerol, 1 mM
Na3VO3, 1 mM PMSF, 1 mM
DTT, protease inhibitors, and 0.1% Triton X-100. The oligonucleotide
sequence used was GTATTTCCCAGAAAAGGAAC. Cell lysates were incubated
with GRR-bound agarose beads, which were then washed and subjected to
SDS-PAGE. Oligo-precipitated proteins were electrophoretically
transferred to nitrocellulose transfer membrane and immunoblotted with
anti-STAT-4 Abs (Santa Cruz Biotechnology).
| Results |
|---|
|
|
|---|
To investigate which signaling pathways are activated by IL-12, we
examined the activation of STAT-4 molecule and several kinases such as
PI3K/Akt, p38 MAPK, and Erk1/2 by immunoblot analysis. As expected,
IL-12 activated STAT-4 and induced their binding to the GRR DNA (Fig. 1
A). When STAT-4 is activated
by IL-12, it is translocated to the nucleus and regulates the
transcription of the IL-12-responsive genes through the binding of
conserved DNA sequences, GRR (23, 24). In addition, the
treatment of IL-12 induced the phosphorylation of p38 MAPK, which was
significantly inhibited by 10 µM p38 MAPK inhibitor, SB203580.
However, Erk1/2 were not activated by the treatment of IL-12. These
results agree well with the previous reports that IL-12 stimulates
MKK6/p38 MAPK, but not Erk1/2 signaling pathway in activated
CD4+ T cells (12, 13). Particularly,
IL-12 induced Akt phosphorylation, which was significantly blocked by
3.5 IC50 (5 µM) of PI3K-specific inhibitor,
LY294002 (25) (Fig. 1
B). As reported previously
(16, 19), IL-2 family cytokines such as IL-2 and IL-4 also
induced Akt phosphorylations, which appeared to be less than those by
IL-12 (Fig. 1
C). Therefore, we demonstrated that, in
addition to STAT-4 and p38 MAPK, IL-12 directly activates the PI3K/Akt
signaling pathway in murine CD4+ T cells.
|
IL-12 has been known as a cytokine that induces the proliferation
of activated CD4+ T cells (3, 5). In
addition, it has also been reported that the PI3K/Akt pathway is an
important cellular signaling pathway that regulates multiple cellular
responses, one of which is to induce cellular proliferation through the
modulation of cell cycle-related molecules such as cyclin D3 and
cyclin-dependent kinase (cdk) inhibitor,
p27kip1 (17, 18). As shown in Fig. 2
A, the proliferation of
CD4+ T cells was enhanced by IL-12 treatment
compared with the cells treated with medium alone. This IL-12 effect
was completely inhibited by LY294002, but not by SB203580, suggesting
that PI3K/Akt, but not p38 MAPK pathway is critical for IL-12-induced
CD4+ T cell proliferation.
|
The PI3K/Akt pathway via IL-12 is not required for
IL-12-induced IFN-
production
One of the important properties of IL-12 is its ability to induce
the production of IFN-
from activated T cells (3). As
expected, IL-12 induced large amounts of IFN-
production from
activated CD4+ T cells, which was inhibited by
the treatment of SB203580 (Fig. 3
). This
result is consistent with previous reports that p38 MAPK pathway is
required for IL-12-induced IFN-
production from activated T cells
(14, 15). In contrast, the treatment of LY294002 did not
significantly inhibit the IL-12-induced IFN-
production, indicating
that PI3K/Akt pathway is not required for IL-12-induced IFN-
production from activated CD4+ T cells.
|
Because IL-12 has been shown to prevent the apoptosis of activated CD4+ T cells in various conditions (3, 6, 7, 8, 9), we tested whether PI3K/Akt pathway is involved in antiapoptotic effects of IL-12 in passive cell death.
Apoptotic T cell death was measured through flow cytometric analysis
stained with both annexin V and propidium iodide (PI). Preactivated
CD4+ T cells showed spontaneous apoptosis over
time, but the addition of IL-12 significantly reduced apoptosis in a
dose-dependent manner (Fig. 4
A), which is consistent with
previous reports (7, 27). As shown in Fig. 4
, B
and C, LY294002 inhibited the antiapoptotic effect
of IL-12 in a dose-dependent manner, but SB203580 did not, suggesting
that IL-12 induces CD4+ T cell survival through
PI3K/Akt pathway, but not through p38 MAPK pathway.
|
|
| Discussion |
|---|
|
|
|---|
The PI3K/Akt signaling pathway is associated with cellular proliferation in T cells. It was reported that IL-2 induces T cell proliferation by modulation of both cyclin D3 and p27kip1 through PI3K/Akt pathway (18). Similarly, IL-12 appeared to regulate these two molecules to induce CD4+ T cell proliferation. However, the expression of cyclin D3, but not that of p27kip1, appeared to be regulated via PI3K/Akt signaling pathway. Previously, it was reported that the regulation of p27kip1 by IL-12 is mediated through STAT-4-dependent pathway (30). In addition to p27kip1, p21WAF1/cip1 has been known as a cdk inhibitor molecule that inhibits cellular proliferation (26). In contrast to p27kip1 regulation, the expression of p21WAF1/cip1 was up-regulated by IL-12 (data not shown). This result was consistent with previous reports that p21WAF1/cip1 is up-regulated following lymphocyte activation, and that the regulation of p21WAF1/cip1 is not required for cytokine-induced T cell proliferation (31, 32). Taken together, it is likely that IL-12 induces CD4+ T cell proliferation through PI3K/Akt pathway-dependent modulation of cyclin D3, a cell cycle-positive regulator molecule, and presumably through STAT-4 pathway-dependent modulation of p27kip1, a cell cycle-negative regulator molecule.
Recently, it has been reported that IL-12 suppresses apoptotic cell
death of activated T cells, but the molecular mechanisms are not clear
yet (3, 6, 7, 8, 9, 33). In this study, we demonstrated that
IL-12 provides survival signals to CD4+ T cells
through the up-regulation of Bcl-2 and cIAP-2, and the down-regulation
of active caspase-3 via PI3K/Akt pathway. Our results are similar to
previous reports that PI3K/Akt signaling pathway via IL-2 family
cytokines promotes T cell survival through the modulation of
antiapoptotic molecule, Bcl-2 (19, 28). In addition, the
activation of PI3K/Akt pathway was reported to prevent the apoptosis of
T cells via NF-
B activation, which was known to induce the
expression of cIAP molecules (34, 35, 36). Bcl-2 eventually
regulates caspase-3 activation through modifying the mitochondrial
membrane potential, and cIAP-2 is potent inhibitor of caspases
(29). Therefore, it is likely that IL-12 inhibits
caspase-3 activation by up-regulation of both Bcl-2 and cIAP-2
molecules through PI3K/Akt pathway. Estaquier et al. (6)
showed that IL-12 prevents apoptosis of CD4+ T
cells induced by anti-Fas or anti-CD3. cIAP-2 has also been
reported to inhibit death receptor-mediated apoptosis through
suppression of caspase-8 activation (35, 36). Therefore,
it is possible that IL-12 may prevent the death receptor-mediated
apoptosis by up-regulation of antiapoptotic molecules such as cIAP-2
through PI3K/Akt pathway.
Even if p38 MAPK pathway is not involved in IL-12-induced T cell
proliferation and antiapoptotic function, this pathway is required for
IL-12-induced IFN-
production from activated
CD4+ T cells (14, 15). It has also
been reported that MKK6/p38 MAPK pathway is involved in IL-12-induced
STAT-4 serine phosphorylation that is important for the
trans-activation activity of STAT-4 (12, 13).
Although we have demonstrated that the PI3K/Akt pathway is not critical
for IL-12-induced IFN-
induction, it should be further studied
whether this pathway is associated with STAT-4 serine phosphorylation.
Consequently, these results suggest that IL-12 differently employs
signaling pathways such as PI3K/Akt, MKK6/p38 MAPK, and Jak/STAT to
perform diverse functions of activated CD4+ T
cells.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Young Chul Sung, Division of Molecular and Life Sciences, Pohang University of Science and Technology, San 31, Hyoja Dong, Pohang, 790-784, Korea. E-mail address: ycsung{at}postech.ac.kr ![]()
3 Abbreviations used in this paper: Jak, Janus kinase; cdk, cyclin-dependent kinase; cIAP, cellular inhibitor of apoptosis protein; Erk, extracellular signal-regulated kinase; GRR, IFN-
response region; LN, lymph node; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; PI, propidium iodide; PI3K, phosphatidylinositol 3-kinase. ![]()
Received for publication April 17, 2002. Accepted for publication July 25, 2002.
| References |
|---|
|
|
|---|
production and type 1 cytokine responses. Immunity 4:471.[Medline]
expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 17:2817.[Medline]
expression. J. Immunol. 165:1374.
. J. Immunol. 157:4781.[Abstract]
B activation, and Bcl-xL levels in vivo. J. Exp. Med. 191:1721.
B control. Proc. Natl. Acad. Sci. USA 94:10057.
B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680.This article has been cited by other articles:
![]() |
C. A. Garcia, H. Wang, M. R. Benakanakere, E. Barrett, D. F. Kinane, and M. Martin c-Jun Controls the Ability of IL-12 to Induce IL-10 Production from Human Memory CD4+ T Cells J. Immunol., October 1, 2009; 183(7): 4475 - 4482. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Verdeil, K. Marquardt, C. D. Surh, and L. A. Sherman Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy PNAS, October 28, 2008; 105(43): 16683 - 16688. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pakpour, C. Zaph, and P. Scott The Central Memory CD4+ T Cell Population Generated during Leishmania major Infection Requires IL-12 to Produce IFN-{gamma} J. Immunol., June 15, 2008; 180(12): 8299 - 8305. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Ruby, R. Montler, R. Zheng, S. Shu, and A. D. Weinberg IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival J. Immunol., February 15, 2008; 180(4): 2140 - 2148. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kim, A. Saudemont, L. Webb, M. Camps, T. Ruckle, E. Hirsch, M. Turner, and F. Colucci The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion Blood, November 1, 2007; 110(9): 3202 - 3208. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-B. Lee, K.-A Lee, and J. Chang Phenotypic changes induced by IL-12 priming regulate effector and memory CD8 T cell differentiation Int. Immunol., September 6, 2007; (2007) dxm072v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini Interleukin-12: Biological Properties and Clinical Application Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Li, S.-i. Kashiwamura, H. Ueda, A. Sekiyama, and H. Okamura Protection of CD8+ T cells from activation-induced cell death by IL-18 J. Leukoc. Biol., July 1, 2007; 82(1): 142 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Yoo, H. Kwon, L.-Y. Khil, L. Zhang, H.-S. Jun, and J.-W. Yoon IL-18 Induces Monocyte Chemotactic Protein-1 Production in Macrophages through the Phosphatidylinositol 3-Kinase/Akt and MEK/ERK1/2 Pathways J. Immunol., December 15, 2005; 175(12): 8280 - 8286. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Riemann, K. Loser, S. Beissert, M. Fujita, A. Schwarz, T. Schwarz, and S. Grabbe IL-12 Breaks Dinitrothiocyanobenzene (DNTB)-Mediated Tolerance and Converts the Tolerogen DNTB into an Immunogen J. Immunol., November 1, 2005; 175(9): 5866 - 5874. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xu, H. Kurihara, T. Ito, H. Kikuchi, K. Yoshida, H. Yamanokuchi, and A. Asari The Keratan Sulfate Disaccharide Gal(6S03) {beta}1,4-GlcNAc(6S03) Modulates Interleukin 12 Production by Macrophages in Murine Thy-1 Type Autoimmune Disease J. Biol. Chem., May 27, 2005; 280(21): 20879 - 20886. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chang, J.-H. Cho, S.-W. Lee, S.-Y. Choi, S.-J. Ha, and Y.-C. Sung IL-12 Priming during In Vitro Antigenic Stimulation Changes Properties of CD8 T Cells and Increases Generation of Effector and Memory Cells J. Immunol., March 1, 2004; 172(5): 2818 - 2826. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Ha, D.-J. Kim, K.-H. Baek, Y.-D. Yun, and Y.-C. Sung IL-23 Induces Stronger Sustained CTL and Th1 Immune Responses Than IL-12 in Hepatitis C Virus Envelope Protein 2 DNA Immunization J. Immunol., January 1, 2004; 172(1): 525 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yoshimoto, M. Furuhata, S. Kamiya, M. Hisada, H. Miyaji, Y. Magami, K. Yamamoto, H. Fujiwara, and J. Mizuguchi Positive Modulation of IL-12 Signaling by Sphingosine Kinase 2 Associating with the IL-12 Receptor {beta}1 Cytoplasmic Region J. Immunol., August 1, 2003; 171(3): 1352 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. H. Koopman, R. R. Bosch, S. E. van Emst-de Vries, M. Spaargaren, J. J. H. H. M. De Pont, and P. H. G. M. Willems R-Ras Alters Ca2+ Homeostasis by Increasing the Ca2+ Leak across the Endoplasmic Reticular Membrane J. Biol. Chem., April 11, 2003; 278(16): 13672 - 13679. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Bruna-Romero, J. Schmieg, M. Del Val, M. Buschle, and M. Tsuji The Dendritic Cell-Specific Chemokine, Dendritic Cell-Derived CC Chemokine 1, Enhances Protective Cell-Mediated Immunity to Murine Malaria J. Immunol., March 15, 2003; 170(6): 3195 - 3203. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |